UCB Expands Immunology Pipeline with Planned Acquisition of Candid Therapeutics and Its Novel T-Cell Engager Platform
UCB has taken a significant step forward in its strategic expansion within immunology by entering into a definitive agreement to acquire Candid Therapeutics, a privately held biotech firm focused on advancing innovative therapies for autoimmune and inflammatory diseases. The transaction underscores UCB’s commitment to strengthening its pipeline through external innovation and highlights its broader ambition to deliver transformative therapies for patients suffering from severe immune-mediated conditions with high unmet medical need.
At the core of this acquisition is cizutamig, Candid’s lead investigational asset, which represents a promising advancement in the emerging field of T-cell engager (TCE) therapies. Cizutamig is a bispecific antibody designed to simultaneously target B-cell maturation antigen (BCMA) expressed on plasma cells and CD3 receptors on T-cells. This dual-targeting mechanism enables the redirection of T-cells to selectively eliminate pathogenic plasma cells and B-cells, which are key drivers in many autoimmune diseases. By harnessing the body’s own immune system to target disease-causing cells, cizutamig offers a novel therapeutic approach that goes beyond traditional immunosuppressive treatments.
Importantly, cizutamig has been engineered with a focus on maintaining potent cytotoxic activity while minimizing cytokine release, a common safety concern associated with T-cell–based therapies. This design feature could potentially translate into an improved safety and tolerability profile compared to earlier-generation TCEs. To date, the molecule has been evaluated in more than 100 patients across multiple clinical studies, including both oncology indications such as multiple myeloma and a range of autoimmune diseases. Its development program is notably broad, currently encompassing more than 10 autoimmune indications, reflecting its potential versatility across diverse disease settings.
The acquisition of Candid Therapeutics builds upon UCB’s recent collaboration with Antengene and illustrates a deliberate, platform-oriented strategy in next-generation immunology. Rather than focusing on a single therapeutic modality, UCB is assembling a diversified portfolio of assets targeting multiple components of the immune system, particularly B-cell biology. This approach is designed to enable more comprehensive and durable disease control by addressing the underlying mechanisms that drive autoimmune pathology.
By integrating Candid’s TCE platform into its existing capabilities, UCB aims to enhance its ability to target antibody-mediated autoimmune diseases through differentiated, biology-driven strategies. These include the selective depletion of pathogenic B-cell populations, which are often responsible for producing autoantibodies that attack healthy tissues. The company’s long-term vision is to achieve what it describes as an “immune reset”—a state in which the immune system is rebalanced to eliminate disease activity while preserving normal immune function.
Jean-Christophe Tellier, Chief Executive Officer of UCB, emphasized the strategic importance of the acquisition, noting that it represents a pivotal milestone in the company’s growth trajectory. According to Tellier, the addition of cizutamig to UCB’s pipeline not only strengthens its technological capabilities but also positions the company at the forefront of a new wave of immunotherapies. He highlighted the potential of TCEs to redefine treatment paradigms for immune-mediated diseases, particularly in cases where existing therapies fail to provide adequate disease control.
Tellier further აღნიშნა that cizutamig could emerge as a transformative asset within UCB’s portfolio, complementing its existing programs and expanding its reach into underserved patient populations. By targeting severe autoimmune diseases with innovative mechanisms of action, UCB aims to set new standards of care and deliver meaningful improvements in patient outcomes and quality of life.
Candid Therapeutics, for its part, brings more than just a single asset to the table. The company has developed a robust pipeline of multi-specific T-cell engager antibodies designed to target different subsets of B-cells involved in autoimmune pathology. This modular, multi-antigen targeting strategy allows for a more comprehensive depletion of disease-causing cells, potentially leading to deeper and more sustained therapeutic responses.
Ken Song, MD, Chairman, CEO, and President of Candid Therapeutics, reflected on the company’s founding vision, which was to redefine the standard of care for immune-mediated diseases through the development of innovative TCE therapies. He noted that Candid has focused on rapidly generating clinical data across multiple indications to identify where its therapies can deliver the greatest benefit to patients. Song expressed confidence that UCB’s extensive experience in immunology, including drug development, regulatory approval, and commercialization, will help accelerate the advancement of Candid’s pipeline and maximize its impact.
The financial terms of the agreement further underscore the strategic value of the acquisition. UCB has agreed to pay $2 billion in upfront consideration, with an additional $200 million tied to potential future milestone payments. This substantial investment reflects both the promise of Candid’s technology platform and UCB’s confidence in its ability to translate these innovations into clinically and commercially successful therapies.
The transaction is subject to customary closing conditions, including regulatory approvals and antitrust clearance, and is expected to be finalized between the end of the second quarter and early third quarter of 2026. Upon completion, Candid Therapeutics will be fully integrated into UCB’s operations, enabling seamless collaboration across research, development, and commercialization functions.
It is important to note that cizutamig remains an investigational therapy and has not yet been approved by regulatory authorities such as the U.S. Food and Drug Administration. As such, its safety and efficacy continue to be evaluated in ongoing clinical trials. Nevertheless, the breadth of its clinical program and the early data generated to date suggest that it holds significant potential as a next-generation treatment for autoimmune diseases.
Advisory support for the transaction has been provided by leading financial and legal firms. Lazard is serving as financial advisor to UCB, with Covington & Burling LLP acting as its legal counsel. On the Candid side, Jefferies LLC and Goldman Sachs & Co. LLC are acting as joint lead financial advisors, with additional support from BofA Securities, Inc. Legal counsel is being provided by Cooley LLP.
Overall, the acquisition of Candid Therapeutics represents a bold and strategic move by UCB to expand its leadership in immunology and accelerate the development of innovative therapies for patients with severe autoimmune diseases. By leveraging cutting-edge T-cell engager technology and integrating it with its existing expertise, UCB is positioning itself to drive the next generation of breakthroughs in immune-mediated disease treatment.
About Candid Therapeutics
Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCEs, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on X: @UCB_news
Source Link:https://www.businesswire.com/
